Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

OMNI BIO PHARMACEUTICAL, INC. (OMBP)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
  Older >>
In millions, except per share itemsMar-31-14Mar-31-13Mar-31-12Mar-31-11Feb-28-11Mar-31-10Feb-28-10Mar-31-09
   10-K10-K10-K10-K10-K10-K10-K/A10-K
Revenues  -0.1-0.10.00.019.77.411.51.3
            Revenue growth  -62.7%-5979.7% -100.0%71.8%479.3% -27.3%
Cost of goods sold  -3.8-11.40.00.019.77.40.01.3
Gross profit  3.811.30.00.00.00.011.50.0
            Gross margin  -7320.5%-8186.8%0.0% 0.0%0.0%100.0%0.0%
Selling, general and administrative   [+]1.75.44.27.618.07.410.31.0
Research and development  0.20.30.40.61.7 1.10.2
Equity in earnings   -0.8-0.6     
Other operating expenses  3.811.3  6.45.617.80.7
EBITDA   [+]-1.9-6.5-5.2-8.2 -13.0 -2.0
            EBITDA margin  3700.7%4705.5%-223012.6% -132.4%-176.1% -156.0%
Depreciation     0.0 0.0 0.0
EBITA  -1.9-6.5-5.2-8.2-26.1-13.0-17.8-2.0
            EBITA margin  3700.7%4705.5%-223012.6% -132.4%-176.1%-155.6%-156.5%
Amortization of intangibles  0.00.00.0     
EBIT   [+]-1.9-6.5-5.3-8.2-26.1-13.0-17.8-2.0
            EBIT margin  3710.3%4708.5%-223887.6% -132.4%-176.1%-155.6%-156.5%
Interest expense, net   [+]   0.00.10.0 0.0
Other income (expense), net   [+]-0.6-1.0-0.10.0-5.0-2.5-5.1-2.5
Pre-tax income  -2.5-7.5-5.4-8.2-31.2-15.5-22.9-4.5
Income taxes  0.00.00.00.00.00.00.00.0
            Tax rate  0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income  -2.5-7.5-5.4-8.2-31.2-15.5-22.9-4.5
            Net margin  4882.4%5399.7%-229791.0% -158.2%-209.9%-200.1%-356.9%
   
Basic EPS   [+]($0.07)($0.23)($0.17)($0.29) ($0.58) ($0.25)
Diluted EPS   [+]($0.07)($0.23)($0.17)($0.29) ($0.58) ($0.25)
   
Shares outstanding (basic)   [+]37.332.031.428.3 26.8 18.3
Shares outstanding (diluted)   [+]37.332.031.428.3 26.8 18.3
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy